2 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow Relapsing-remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis CLS12311 low, CLS12311 medium, CLS12311 high - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 1 | Completed | Cellerys AG | 11 | 2024-06-18 | 2026-06-08 |
| Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). Arm 1 - GEH120714 (18F) Injection - Relapsing-remitting Multiple Sclerosis (rrMS) | Phase 1 | Completed | GE Healthcare | 30 | 2013-04-01 | 2017-02-24 |
Multiple Sclerosis, Relapsing-Remitting (2)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Multiple Sclerosis (2) · Nervous System Diseases (2)
Injections (1)
Cellerys AG (1) · GE Healthcare (1)
Canada (1) · Czechia (1) · Germany (1) · Italy (1) · Switzerland (1)